drugset / Trial / NCT00368706

A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients

NCT00368706

Phase 3 Completed 246 enrolled Astellas Pharma Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid

Timeline

Start
2006-09
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule 5 mg Oral
Comparator Tolterodine Small molecule Oral

Indications